SMS Pharmaceuticals Limited — Updates, 10-08-2025: Press Release

SMS Pharma reported strong Q1FY26 financial results: Revenue jumped 19% YoY to ₹196.05 Cr, and PAT surged 24% YoY to ₹20.50 Cr, with EBITDA margin stable at 20%. The company successfully commissioned backward integration for key APIs, which is expected to improve future margins. SMS Pharma plans to double R&D investment over 18 months, targeting ~30 new filings. A ₹250 Cr capex plan is underway for capacity expansion, a peptide R&D facility, and a CDMO greenfield site. The company remains on track for 20% revenue growth and over 20% EBITDA margin in FY26.